Market Research Logo

Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021

Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021

About CINV Drugs

The launch of extended half-life drugs in the market is expected to substantially improve the adoption rates, owing to their ability to act for prolonged periods of time. For instance, Heron Therapeutics' SUSTOL and Tesaro's VARUBI offer protection against CINV for five days and seven days, respectively. Additionally, the emergence of oral therapies is expected to enhance the patient compliance, resulting in market growth.

Technavio’s analysts forecast the global CINV drugs market to grow at a CAGR of 5.41% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global CINV drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of CINV drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report Global Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • GlaxoSmithKline
  • Helsinn
  • Heron Therapeutics
  • Merck
  • Tesaro
Other prominent vendors
  • Acacia Pharma
  • Aphios
  • Baxter Healthcare
  • Dr. Reddy's Laboratories
  • Eisai
  • Especificos Stendhal
  • F. Hoffmann-La Roche
  • Kyowa Hakko Kirin
  • Lee’s Pharmaceutical Holdings
  • Midatech Pharma
  • Mundipharma
  • Mylan
  • Ono Pharmaceutical
  • OPKO Health
  • Orchid Chemicals & Pharmaceuticals
  • Otsuka Pharmaceutical
  • Purdue Pharma
  • Sandoz (a subsidiary of Novartis)
  • SciClone Pharmaceuticals
  • Shin Nippon Biomedical Laboratories
  • Solasia Pharma K.K.
  • Specialised Therapeutics
  • Sun Pharma
  • Taiho Pharmaceutical
  • Teva Pharmaceuticals
Market driver
  • Growing preference of chemotherapy drugs in developing countries
  • For a full, detailed list, view our report
Market challenge
  • Growing popularity of alternate therapies for the treatment of cancer in developed countries
  • For a full, detailed list, view our report
Market trend
  • Increasing inorganic growth strategies likely to fuel the market growth
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global CINV Drugs Market 2017-2021

Technavio recognizes the following companies as the key players in the global CINV drugs market: GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, and Tesaro

Other Prominent Vendors in the market are: Acacia Pharma, Aphios, Baxter Healthcare, Dr. Reddy's Laboratories, Eisai, Especificos Stendhal, F. Hoffmann-La Roche, Kyowa Hakko Kirin, Lee’s Pharmaceutical Holdings, Midatech Pharma, Mundipharma, Mylan, Ono Pharmaceutical, OPKO Health, Orchid Chemicals & Pharmaceuticals, Otsuka Pharmaceutical, Purdue Pharma, Sandoz (a subsidiary of Novartis), SciClone Pharmaceuticals, Shin Nippon Biomedical Laboratories, Solasia Pharma K.K., Specialised Therapeutics, Sun Pharma, Taiho Pharmaceutical, and Teva Pharmaceuticals

Commenting on the report, an analyst from Technavio’s team said: “The high unmet medical need in the market has driven the R&D activities of existing as well as new vendors. Helsinn is one of the leading companies that has a strong pipeline of CINV drugs with two drug candidates in Phase III and Phase I stages. Helsinn has collaborated with Taiho Pharmaceutical for the development and commercialization of netupitant IV in Japan. Heron Therapeutics is developing HTX-019, currently in Phase I stage, for the prevention and treatment of CINV. In addition, new vendors such as Shin Nippon Biomedical Laboratories and Acacia Pharma are aggressively advancing their pipeline to launch new drugs during the forecast period. Shin Nippon Biomedical Laboratories and Acacia are developing granisetron intranasal and APD403, respectively. Both these drugs are in Phase II development stage. These pipeline drugs are expected to gain approval during the forecast period and will likely fuel the market growth.”

According to the report, the high unmet medical need in the market has driven the R&D activities of existing as well as new vendors. Helsinn is one of the leading companies that has a strong pipeline of CINV drugs with two drug candidates in Phase III and Phase I stages. Helsinn has collaborated with Taiho Pharmaceutical for the development and commercialization of netupitant IV in Japan. Heron Therapeutics is developing HTX-019, currently in Phase I stage, for the prevention and treatment of CINV. In addition, new vendors such as Shin Nippon Biomedical Laboratories and Acacia Pharma are aggressively advancing their pipeline to launch new drugs during the forecast period. Shin Nippon Biomedical Laboratories and Acacia are developing granisetron intranasal and APD403, respectively. Both these drugs are in Phase II development stage. These pipeline drugs are expected to gain approval during the forecast period and will likely fuel the market growth.

Further, the report states that patent expiries result in the loss of market exclusivity of a drug, which will result in a rapid decline in its sales. This will further lead to the market entry of cost-effective generic versions that have a similar efficacy and safety profile as the branded therapy. The patents of majority of the CINV therapeutics have either expired or are set to expire at the end of the forecast period. For instance, Zofran by GlaxoSmithKline lost its patent exclusivity in 2005 and Kytril by F. Hoffmann-La Roche in 2007. This led to the market entry of their generics, reducing their sales. Similarly, EMEND by Merck and Aloxi by Helsinn lost their patent exclusivities in April 2015, leading to the availability of their generics in the market. EMEND reported a YoY decline of 3.3% owing to patent expiry covering product's oral dosage form in 2015. Therefore, loss of patent expiries will substantially impact the market growth.

Companies Mentioned

GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, Tesaro, Acacia Pharma, Aphios, Baxter Healthcare, Dr. Reddy's Laboratories, Eisai, Especificos Stendhal, F. Hoffmann-La Roche, Kyowa Hakko Kirin, Lee’s Pharmaceutical Holdings, Midatech Pharma, Mundipharma, Mylan, Ono Pharmaceutical, OPKO Health, Orchid Chemicals & Pharmaceuticals, Otsuka Pharmaceutical, Purdue Pharma, Sandoz (a subsidiary of Novartis), SciClone Pharmaceuticals, Shin Nippon Biomedical Laboratories, Solasia Pharma K.K., Specialised Therapeutics, Sun Pharma, Taiho Pharmaceutical, Teva Pharmaceuticals.

  • Executive summary
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Highlights
  • Disease overview
    • Understanding the disease
    • Pathophysiology
    • Central pathway
    • Peripheral pathway
    • Management of disease
  • Pipeline analysis
    • Table Pipeline landscape
    • Table Key pipeline candidates
  • Market landscape
    • Global CINV drugs market
      • Table Global CINV drugs market snapshot
      • Table Analysis of global CINV drugs market
      • Table Global CINV drugs market 2016-2021 ($ billions)
      • Table Key initiatives in emerging economies
      • Table Opportunity analysis of global CINV drugs market
      • Table Opportunity analysis in developed and emerging markets
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by therapy
    • Table Segmentation of global CINV drugs market by therapy 2016 (% share)
    • Table Lifecycle analysis of segments in global CINV drugs market
    • Serotonin receptor antagonists
    • NK1 receptor antoagonists
    • Others
  • Geographical segmentation
    • Table Geographic segmentation by revenue 2016 and 2021
    • Table Geographic segmentation by revenue 2016 ($ millions)
    • CINV drugs market in Americas
      • Table Market scenario in Americas
      • Table CINV drugs market in Americas 2016-2021 ($ millions)
    • CINV drugs market in EMEA
      • Table Market scenario in EMEA
      • Table CINV drugs market in EMEA 2016-2021 ($ millions)
    • CINV drugs market in APAC
      • Table Market scenario in APAC
      • Table CINV drugs market in APAC 2016-2021 ($ millions)
      • Table Key drivers and challenges in APAC
  • Market drivers
    • Growing cancer population driving the market growth
      • Table Top ten cancers in the US in 2013
    • Growing preference for chemotherapy drugs in developing countries
    • Approval of new drugs fuels the market growth
      • Table Key approvals in the market in 2015 and 2016
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Growing popularity of alternate therapies for the treatment of cancer in developed countries
    • Loss of patent exclusivities increasing generic competition
      • Table Merck: YoY revenue and growth rate of EMEND 2013-2015 ($ millions)
    • Limitations in existing therapies hindering the growth prospects
      • Table Forcefield analysis of drivers and challenges
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Robust R&D activities fueling the pipeline
      • Table Key vendors that are extensively conducting R&D activities
    • Increasing inorganic growth strategies likely to fuel the market growth
    • Novel treatment options coupled with new applications
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global CINV drugs market 2015
      • Table Market share analysis in global CINV drugs market
      • Table Competitive analysis of global CINV drugs market
      • Table Market penetration of various global CINV drugs manufacturers 2015
  • Key vendor analysis
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Strength assessment
      • Table GlaxoSmithKline: Strategy assessment
      • Table GlaxoSmithKline: Opportunity assessment
    • Helsinn
      • Table Helsinn: Key highlights
      • Table Helsinn: Strength assessment
      • Table Helsinn: Strategy assessment
      • Table Helsinn: Opportunity assessment
    • Heron Therapeutics
      • Table Heron Therapeutics: Key highlights
      • Table Heron Therapeutics: Strength assessment
      • Table Heron Therapeutics strategy assessment
      • Table Heron Therapeutics: Opportunity assessment
    • Merck
      • Table Merck: Key highlights
      • Table Merck: strength assessment
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
      • Table Merck: YoY revenue and growth rate of EMEND 2013-2015 ($ millions)
    • Tesaro
      • Table Tesaro: Key highlights
      • Table Tesaro: Strength assessment
      • Table Tesaro: Strategy assessment
      • Table Tesaro: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report